

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

CLARIFICATION ANNOUNCEMENT
IN RELATION TO GRANT OF RESTRICTED SHARES

References are made to (i) the circular of Genscript Biotech Corporation (the “**Company**”) dated 22 April 2024 and the announcement of the Company dated 23 June 2024 in relation to, among others, the approval of the proposed amendments to the RSA Scheme 2021 and the proposed refreshment of the scheme mandate limit by the shareholders of the Company (“**Shareholders**”) at the annual general meeting of the Company held on 21 June 2024 (the “**AGM**”) and (ii) the announcement of the Company dated 8 July 2024 (the “**Previous Announcement**”) in relation to, among others, the grant of the RSA Shares by the Company to consultants engaged by the Company pursuant to the RSA Scheme 2021 (the “**RSA Grant**”). Capitalised terms used herein shall have the same meanings as those defined in the Previous Announcement unless the context otherwise requires.

The Board would like to clarify that, following the abovementioned amendments and refreshment as approved at the AGM coming into effect, the RSA Grant will not be satisfied by issue and allotment of new Shares pursuant to the General Mandate granted by the Shareholders of the Company at the AGM. For the avoidance of doubt, as at the date of this announcement, no Shares have been issued under the General Mandate. Accordingly, up to 425,537,303 Shares, representing 20% of the total number of Shares in issue (excluding treasury shares, if any) as at the date of the AGM, remain available for future allotment and issue of Shares under the General Mandate.

The RSA Grant will be satisfied by issuance and allotment of 68,054 RSA Shares to the Trustee or the nominee account of the Company (of which the beneficial owner will be the relevant RSA Grantees) within the scheme mandate limit, being the mandate granted to the Board to grant share options and/or awards over new Shares of the Company under the RSA Scheme 2021 and any other share schemes adopted by the Company and in accordance with the terms of the RSA Scheme 2021. The new Shares so issued will be held on trust for the RSA Grantees until the end of each vesting period and be transferred to the respective RSA Grantees upon the end of each vesting period.

Save for the above clarification, all information set out in the Previous Announcement remains unchanged.

By Order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 9 July 2024

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Director is Dr. Wang Luquan; and the independent non-executive Directors are Mr. Dai Zumian, Mr. Pan Jiuan, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.